You are currently viewing our site as a guest, which gives you limited access to our site features. By signing up for a free membership, you will receive our Investment Opportunity newsletters and have access to additional features for finding and comparing managed funds and shares. Registration is fast and simple, so please:
Business Description: Universal Biosensors Inc. (UBI) is a specialist medical diagnostics company focusing on research, development, manufacture and commercialisation of in vitro diagnostic devices for consumer and professional point of care use. UBI has developed a blood glucose monitoring product that is being commercialised globally by LifeScan, Inc. a Johnson & Johnson company.
Strategy Analysis: UBI's strategy involves: manufacturing blood glucose test strips for LifeScan; providing post market support services to LifeScan in connection with the blood glucose test; continuing to undertake contract research and development work on behalf of LifeScan and seeking to develop additional products in the field of diabetes and blood glucose monitoring for LifeScan; extending the electrochemical cell technology by developing new non-blood glucose tests and; entering into collaborative arrangements or strategic alliances with other life sciences companies or other industry participants to complete the development and commercialisation of UBI's non-blood glucose tests.
Universal Biosensors reported net loss of $9.13m for the year ended 31 December 2012. Revenue from ordinary activities were $29.65m. Basic and Diluted EPS were (5.7) cents compared to (9) cents last year. The net operating cash outflow was $3.3m compared to an outflow of $7.16m in the pcp. No dividend was declared.
The Age 19/06/2013 |
The bullish sentiments on the sharemarket earlier this year have been challenged by a correction that has taken the All Ordinaries Index down about 10 per cent from its May highs. Many investors are now asking how deep the current correction is likely to be.
The Age 19/06/2013 |
Done well, value investing is a successful, safe way to invest. The logic of the approach - buying an asset for less than its underlying value - is irrefutable.
The Age 19/06/2013 |
Snowballing debts and no means to repay them ... going bankrupt is the last-ditch option for those in a financial hole too deep to climb out from.
The Age 19/06/2013 |
One of the weapons an individual has over institutions is time, and with real value emerging at the micro-cap end of the market, smaller stocks are an area worth holding on to.
The Age 19/06/2013 |
Spending 10 days in Japan gives one a good overview of what they call "Abenomics" and its impact, and that includes also being here for one of the biggest drops on the Japanese market in weeks.
The Age 19/06/2013 |
Lend Lease has moved to allay investors' concerns with the issue of a formal profit guidance of between $540 million and $550 million for the full year, despite the weakness in the construction sector.
Already a member? 
$ 0.660
